The COMPASSHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer): COMPASSHER2 Residual Disease (RD) A Double-Blinded Phase III Randomized Trial of T-DM1 Compared with T-DM1 and Tucatinib

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Her2-positive Breast Cancer
  • Age: Between 18 - 100 Years
  • Gender: Female
  • Other Inclusion Criteria:
    1) ECOG Performance Status 0-1. 2) Adequate hepatic, renal, and bone marrow function. 3)Not pregnant and not nursing.

You may not be eligible for this study if the following are true:

  • 1) Patients with known active and/or untreated Hepatitis B or Hepatitis C or chronic liver disease are ineligible. 2) History of any prior (ipsi- or contralateral) invasive breast cancer within 3 years of registration. 3) Evidence of recurrent disease following preoperative therapy and surgery. 4) History of exposure to the following cumulative doses of anthracyclines: Doxorubicin > 240 mg/m2; Epirubicin or Liposomal Doxorubicin-Hydrochloride (Myocet┬«) > 480 mg/m2. For other anthracyclines, exposure equivalent to doxorubicin > 240 mg/m2.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.